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Angiogenesis, the growth of new blood vessels, is a fundamental physiological pro-
cess. It is also of great significance during the development of tumours, which rely
on blood vessels for supply of nutrients and oxygen and for the spreading of metas-
tases. We studied the formation of capillaries using the established cell culture mo-
del of human endothelial cells plated on Matrigel, a three-dimensional extracellular
matrix. Using quantitative mass spectrometry, we identified almost 8000 proteins
and their regulation pattern during capillary morphogenesis.
Among the most upregulated proteins, we propose C-type lectin family 14 member
A (CLEC14A) as a novel vessel marker. We characterized CLEC14A as a highly gly-
cosylated transmembrane protein with a set of distinctly regulated phosphorylation
sites on its cytoplasmic tail. In an attempt of elucidating the interaction and signal-
ling network of CLEC14A, we identified LanC-like protein 1 (LANCL1) as specific
interactor of the C-terminus of CLEC14A in its phosphorylated state.
Our findings will contribute to the understanding of the complex interplay of mole-
cular mechanisms regulating vessel formation.
Zusammenfassung
Angiogenese, das Wachstum neuer Blutgefäße, ist ein fundamentaler physiologi-
scher Prozess. Dieser ist unter anderem von großer Bedeutung bei der Tumorent-
wicklung, da Tumore auf Blutgefäße für ihre Versorgung mit Nährstoffen und Sau-
erstoff und für das Streuen von Metastasen angewiesen sind. Wir haben die Ent-
stehung von Kapillaren anhand eines etablierten Zellkulturmodells untersucht, bei
dem menschliche Endothelzellen auf Matrigel kultiviert werden, einer dreidimen-
sionalen extrazellulären Matrix. Mit Hilfe von quantitativer Massenspektrometrie
konnten wir annähernd 8000 Proteine und ihr Regulationsmuster während der Ka-
pillarbildung identifizieren.
Unter den am stärksten hochregulierten Proteinen ist CLEC14A, ein C-Typ Lektin,
welches wir als neuen Blutgefäßmarker vorschlagen. Wir haben CLEC14A als hoch-
glycosyliertes Transmembranprotein charakterisiert, das in seinem cytoplasmati-
schen Teil einige spezifisch regulierte Phosphporylierungsstellen besitzt. Als Beitrag
zur Entschlüsselung des Signal- und Interaktionsnetzwerks von CLEC14A konnten
wir LANCL1 als Interaktionspartner von CLEC14A identifizieren, der spezifisch den
phosphorylierten C-Terminus bindet.
Diese Erkenntnisse werden das Verständnis des komplexen Zusammenspiels der
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The cardiovascular system constitutes the principal network for distributing nu-
trients, gases and signalling molecules in the body. In compliance with this funda-
mental significance, it is the first functional organ which develops in the vertebrate
body during ontogenesis [1]. The de novo formation of blood vessels in the embryo
is defined as vasculogenesis [2]. It involves the differentiation of mesodermal stem
cells into angioblasts and further into vascular endothelial cells. Endothelial cells
are capable of producing a basal lamina and forming a lumen. They will later cover
the entire inner surface of all blood vessels. During later stages of development,
new vessels form by sprouting or intussusception from pre-existing ones, a process
termed angiogenesis [3].
Angiogenesis occurs physiologically in growth and development and during wound
healing. Pathologically, angiogenesis is of great significance for tumour progression:
First, proliferating tumours rely on vascularization to meet their metabolic needs
(fig. 1.1).
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Figure 1.1: Significance of Tumour Angiogenesis.
Tumour development is initiated by mutations that cause oncogene activation. Apoptotic cell death
is initially opposing tumour cell proliferation, until a subpopulation acquires defects in apoptosis.
Proliferation progresses until the tumour reaches a critical size at which its centre is cut off the blood
supply. A high percentage of humans at a certain age are thought to carry such in situ tumours without
symptoms of disease [4]. Some tumours trigger the “angiogenic switch”, by which they succeed to
trigger the invasive growth of newly formed blood vessels. This cures the tumour of hypoxia and
metabolic stress and allows malignant progression. Adapted from ref. [5].
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Second, angiogenesis allows the infiltration of the tumour by leukocytes, which pro-
vide chemokines and proteases, thereby assisting the detachment of tumour cells,
their migration into the bloodstream and the formation of metastases [6]. Finally,
also metastases need to become vascularized in order to grow [7].
The concept of tumourigenesis relying on angiogenesis was first proposed by Judah
Folkman in 1971 [8] and has launched the field of anti-angiogenic cancer the-
rapy.
1.1.1 Morphology and Signalling of Angiogenesis
Endothelial cells together with pericytes are the major players in angiogenesis. The
sprouting of blood vessels comprises several consecutive steps, as outlined in fig.
1.2; these include the local degradation of the basement membrane, migration of
endothelial cells, bipolar alignment, lumen formation and cell adhesion, and finally





Figure 1.2: Morphological Changes During Angiogenesis.
a) A capillary lumen is lined by endothelial cells (red), which rest on a basement membrane (purple).
Pericytes (green) are lain against the outside of the basement membrane. b) Angiogenic stimuli lead
to the detachment of pericytes. c) This allows the degradation of the basement membrane and the
migration of endothelial cells towards the chemotactic signal. d) Endothelial cells proliferate and
stretch to form a capillary sprout. e) The sprouts form a lumen, accompanied by the formation of
a new basement membrane and the attachment of pericytes. Finally, two sprouts fuse by a scarcely
known mechanism. From ref. [10].
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All of these processes are tightly regulated by activating and inhibiting molecules,
which include mainly cytokines and growth factors, among them the members of
the vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)
families [11].
The last two decades have revealed many proteins that are involved in the orches-
tration of the cellular events during angiogenesis: VEGF can be induced by a range
of stimuli, e. g. hypoxia, and triggers tyrosine kinase pathways by binding to VEGF
receptors, such as FLK1. Early responses to VEGF include an increased permeability
of the vessels, mediated via vascular endothelial cadherin (VE-cadherin), the major
adhesion molecule controlling cell to cell contacts in the endothelium [12, 13]. Ma-
trix metalloproteases (MMPs) are then secreted in order to degrade the basement
membrane [14]. Subsequent cell migration and remodelling events critically rely
on integrin-mediated cell adhesion processes [15]. Next to VEGF and its receptors,
the angiopoietin/TIE and ephrin-B/Eph-B systems of ligands and receptors mediate
similar effects during later stages of angiogenesis [9].
Antiangiogenic molecules, such as angiostatin and thrombospondin-1, are known
to counteract VEGF and other proangiogenic effectors.
Antiangiogenic therapy is promising to fight cancer and other diseases dependent
on angiogenesis in a targeted fashion, thereby reducing adverse side effects. Com-
pounds currently in clinical use mostly target VEGF signalling, either directly such
as Bevacizumab, a monoclonal antibody against VEGF-A, or by blocking downs-
tream receptor tyrosine kinases, such as Sunitinib, a small molecule inhibitor [16].
A detailed understanding of the interplay of molecular mechanisms regulating ves-
sel formation is critical for the identification of new pharmacological targets and
the development of new drugs.
1.1.2 Angiogenesis in vitro
Given the complexity of events during angiogenesis, it was long difficult to study
this process. Early studies relied exclusively on animal models, involving e. g. the
implantation of tumour tissue into laboratory animals and monitoring their vascu-
larization. Later, an assay based on the chick embryo chorioallantoic membrane
was developed, allowing for the screening of angiogenic regulators using chicken
eggs. Only in 1980 it was discovered that angiogenesis can be studied using in vi-
tro models of endothelial cells cultured in appropriate media and plated on special
matrices. Endothelial cells were able to form tubular networks in vitro, which were
almost identical, by light and electron microscopy, to capillary vascular beds in vivo.
The morphological changes in these setups occurred slowly, generally requiring the
cells to be kept in culture for many weeks [17].
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In 1982, it was discovered that the Engelbreth-Holm-Swarm (EHS) sarcoma in mice
had the unique property of producing extracellular matrix components that are dis-
tinct from cartilage but instead resemble the basement membrane [18]. Laminin
I, type IV collagen, perlecan (heparan sulfate proteoglycan) and nidogen/entactin
were identified as major constituents, next to growth factors and several matrix
proteases. The mixture can be extracted in the cold and forms a gel when brought
to body temperature.
A range of cell types show distinct growth or differentiation behavior when pla-
ted on EHS matrix [19]. Most significantly, endothelial cells were shown to form
capillary-like structures. The process occurred within a few hours, compared to
weeks in previous setups, and included distinct steps of cell adhesion, migration,
alignment, protease secretion, and tubule formation. [20]. This underlined the
significance on the interaction of endothelial cells with their surrounding matrix
during angiogenesis.
Today, the EHS matrix is commercially available as “Matrigel” and is used in a ple-
thora of cell biological assays [21, 22]. Among them are screens for angiogenic
and anti-angiogenic molecules, which can be performed in high throughput and
respond to almost all known regulatory factors [23]
1.1.3 C-Type Lectins
Lectins comprise a large family of carbohydrate-binding proteins, found ubiqui-
tously in all kinds of taxa. They are usually large, multidomain proteins, yet
the sugar-binding activity can be generally ascribed to a distinct carbohydrate-
recognition domain (CRD) within the protein [24]. CRDs are structurally diverse
and named only by their common function.
Animal lectins localize either within intracellular compartments, on the cell surface
or are secreted. They function in (glyco)protein quality control, sorting and traf-
ficking inside the cell, whereas they mediate cell-cell or cell-matrix recognition in
the extracellular space.
One subgroup of lectins are the Ca 2+-dependent type (C-type) lectins, which are in
turn divided into several families. All members share the conserved C-type lectin
domain (CTLD), which is one class of CRDs. Next to their carbohydrate binding ac-
tivity, CTLDs frequently serve in protein interaction and binding is not always Ca 2+-
dependent [24]. Some CTLDs even lack the conserved motifs that are connected
with sugar binding [25], among them all members of the family 14, or endosialin
family, shown in fig. 1.3.
The endosialin family comprises four members: endosialin (CD248; tumour endo-
thelial marker 1, TEM1), thrombomodulin (CD141), complement component C1q



















Figure 1.3: C-Type Lectin Family 14. All four members of the family 14 of C-type lectins share a set
of conserved domains: the prototypical C-type lectin domain, the sushi domain, a number of EGF-like
repeats and a proline, serine, threonine rich mucin-like domain. The C-terminal three amino acids of
cytoplasmic act as a PDZ binding motif in some members.
epidermal growth factor receptor 5, EGFR5). All members of the Endosialin family
are type I transmembrane proteins with sizes of the processed forms ranging from
469 to 740 amino acids. The large N-terminal extracellular domains all contain
the eponymous C-type lectin domain, followed by a sushi domain (complement
control protein domain, CCP domain), 2–6 epidermal growth factor (EGF)-like re-
peats and a loosely defined serine/threonine/proline-rich mucin-like domain of va-
riable length. All mucin-like domains feature many potential O-glycosylation motifs
and a strong O-glycosylation pattern was published in the case of endosialin [26].
The short cytoplasmic tails of 36–72 amino acids show little conservation among
the paralogs.
The C-terminal 3 amino acids of C1qR were reported to function as a PDZ binding
motif, which interacts with the PDZ domain of the protein GIPC1 [27]. The PDZ
domain is named after the proteins PSD95, DlgA and zo-1, which were first shown
to contain this domain.
By homology also endosialin contains the PDZ binding motif [26], yet no interac-
tion partner(s) are known [28]. The extreme C-terminus of CLEC14A (amino acids
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SDA) is identical to the PDZ binding motif in integrin alpha-5 and homologous to
the sequence SEA in neuropilin-1, both of which were also shown to interact with
GIPC1 [29, 30]. The respective sequence in thrombomodulin does not match the
PDZ binding motif consensus.
Phosphorylation in the vicinity of PDZ binding motifs may influence the binding
of PDZ domain containing proteins, and thereby serve as a regulatory mechanism.
This was shown in the case of the C-terminus of the K+-channel Kir 3.2 binding to
the PDZ domain protein PSD-95 [31].
1.1.4 Role of C-Type Lectin Family 14 Members in Angiogenesis
Endosialin was shown to be involved in tumour angiogenesis. It was discovered
as tumour stromal antigen, expressed in vascular endothelial cells of malignant
tumors [32]. Later, it was identified in a transcriptomic study that compared en-
dothelia derived from tumours with ones derived from normal tissue. The protein
was named tumour endothelial marker 1 (TEM1) for its distinct association with
tumour-derived endothelia [33]. In another study based on the affinities of mo-
noclonal antibodies, it was reported that endosialin is a cell surface glycoprotein
which is predominantly expressed by fibroblasts and a subset of pericytes, that are
associated with tumour vessels but not by tumour endothelium itself [34]. This dis-
crepancy is matter of ongoing debate [28]. It is important to note that endosialin
is not expressed in HUVECs ex vivo [26].
Endosialin knockout mice exhibit no difference to wild type animals in develop-
ment, wound healing and tumour development [35]. However, there was a striking
reduction in tumour growth, invasiveness, and metastasis after transplantation of
tumours to abdominal sites in knockout mice. At the same time tumours were vas-
cularized with a lot more small instead of medium and large vessels. These findings
indicate a potential function for endosialin in vessel maturation and growth.
C-type lectin family member 14A is the fourth and largely uncharacterized member
of the endosialin family [25]. There is very few experimental data about CLEC14A.
One microarray study described CLEC14A expression to be endothelial cell restric-
ted [36] (referred to as AW770514). Another study reported expression of mouse
CLEC14A in the developing brain, and widely expressed in the adult body [37]
(referred to as Ceg1).
Here, we report the first thorough characterization of CLEC14A as novel vessel
marker, that is highly upregulated in HUVECs on Matrigel.
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1.2 Mass Spectrometry Based Proteomics
Science has long sought to describe a given biological system, e. g. a cell, tissue or
organism, in its totality. Fields of research that aim to provide information on such
a global scale are referred to by the ending “-omics”.
A general concept of scientific discovery, especially in “omics” fields involves the
relative comparison of different functional states of a biological system. Many ap-
proaches have been developed to deliver a comprehensive and unbiased compari-
son of two such states, but the task remains daunting.
Genomics research first was able to address biological questions comprehensively
on the level of DNA. The field benefited greatly from a straightforward methodology
based on oligonucleotide synthesis, hybridization and amplification by polymerase
chain reaction [38]. Yet, biological effects are generally mediated by molecules that
are located further downstream in the flow of genetic information: RNA species in
some processes, but proteins in most cases.
The term “proteome” describes the entirety of proteins found in a given biological
system. In contrast to the genome, the proteome is a highly dynamic ensemble: It
follows internal (e. g. periodic) fluctuations and responds to external stimuli. Pro-
teomic changes are achieved through altered rates of protein synthesis and protein
degradation as well as through the activity of protein modifying enzymes.
More than a decade ago, the advent of DNA microarray technology, which harnesses
the nucleic acid based methodology [39, 40], had paved the way to transcripto-
mics. The transcriptomic approach seeks to deduce functional information about
protein expression from the levels of the corresponding mRNA transcripts. By using
differentially labelled cDNA probes, microarrays allow the comparison of multiple
functional states of a cell or tissue. However, it was shown that the levels mRNA
and protein expression poorly correlate [41].
The recent development of ribosome profiling [42] allows a focused and quantita-
tive view on those mRNA regions that are eventually transcribed. This approach
yields expression data that correlate much better with the actual protein levels,
but it is still far from being applicable on a general basis: It requires large sample
amounts, involves many experimentally challenging steps and relies on expensive
deep sequencing.
The chemical diversity of proteins has long hampered the development of methods
for the comprehensive high-throughput analysis of the proteome. In recent years,
mass spectrometry (MS) based approaches are emerging as the gold standard of
proteomics research [43] and have proven capable of covering near-complete pro-
teomes of eukaryotic cells [41].
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This development was enabled by advances in sample preparation [44, 45], the
establishment of quantitative methods [46], the advent of high-resolution mass
spectrometers [47–49] and robust and automated workflows for bioinformatic ana-
lysis of the vast quantities of raw data [50].
1.2.1 General Workflow of Mass Spectrometry Based Proteomics
proteolysisextraction
ESI








































































Figure 1.4: Basic Workflow of MS-Based Proteomics As Performed in Our Laboratory.
For details see main text.
A typical mass spectrometry based proteomic experiment follows the “bottom up”
and “shotgun” principles, see fig. 1.4. Proteins are first extracted from the samples
to be analysed, and digested into peptides, which are easily amenable to mass spec-
trometric analysis. Depending on the sample complexity, one- or multi-dimensional
fractionation can be performed on the protein and/or peptide level. Each fraction is
then further separated by high performance liquid chromatography (HPLC). The ef-
fluent of the HPLC column is subjected to electrospray ionization (ESI) and directly
sprayed into the mass spectrometer. The mass spectrometer generally records full
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MS spectra, alternating with fragmentation spectra (MS/MS) of the most abundant
ions that are eluting at the given time.
“Shotgun” refers to the peptides being selected for fragmentation in a more or less
non-targeted fashion. The identity of a peptide is deduced from its precursor mass
and its characteristic fragment ion pattern. The proteins present in the mixture
are later being reconstructed from the identified peptides (hence “bottom up”) du-
ring data analysis. This approach has its drawbacks, especially for the analysis of
proteins with partial sequence identity, such as isoforms and splice variants, which
need to be investigated based on peptides unique for one distinct protein species
[51]. Yet, in terms of robustness, universality and throughput, it is far superior to
the “top down” approach which starts from intact proteins.
1.2.2 Quantitative Mass Spectrometry
In many analytical setups, mass spectrometry is applied solely as a qualitative me-
thod used to identify proteins. However, quantitative information can be extracted
from mass spectra and provides valuable information.
Mass spectrometry is not inherently quantitative, i. e. the intensity readout from
the mass spectrometer is not directly correlated with the amount of peptide that
was injected. This is largely a consequence of the different ionization propensities
of different peptides, which in turn is caused by their chemical diversity.
A range of approaches have been developed to provide relative or absolute quanti-
tative information. Many rely on labelling of peptide species with stable isotopes.
This retains most of the chemical properties of the peptide while inducing a detec-
table mass shift, thereby allowing the relative quantification of the labelled versus
the unlabelled form. Labelling can be performed chemically on the protein or pep-
tide level, e. g. by using the ICAT [52] or iTRAQ reagents [53]. Alternatively, labels
can be introduced metabolically e. g. by growing cells in media containing isotope-
labelled compounds. The labelling method has consequences for the amenability
of the samples and the error susceptability: Metabolic labelling was first only appli-
cable to cells and unicellular organisms, but has recently been extended to higher
organisms such as the mouse [54]. Human tissue samples and clinical specimen ob-
viously cannot be labelled metabolically and are only amenable to chemical labels,
which can be applied on virtually any sample. Chemical labelling is performed
rather late in the experimental workflow, thereby reducing the quantification ac-
curacy due to variations caused by separate manipulation, whereas metabolically




Figure 1.5: Labelling Approaches
and Quantitative Accuracy.
Blue and yellow boxes represent
the different experimental condi-
tions that are to be labelled and
compared. After introduction of the
label, the samples can be combi-
ned (horizontal lines) and from the-
reon be processed together. Dashed
boxes and lines indicate stages of
parallel handling, where uncompen-
sated errors can occur that decrease
the quantitative accuracy.
















One popular and straightforward method of metabolic labelling is SILAC (stable
isotope labelling by amino acids in cell culture), which was developed in our lab
[56, 57]. Typically, cells are cultured in media containing either normal (“light”)
or labelled (“heavy”) versions of essential amino acids such as arginine and lysine.
In combination with the protease trypsin, which cleaves after exactly these amino
acids [58], this results in one labelled amino acid per tryptic peptide, thereby in-
troducing known mass shifts. By combining different versions of labelled amino
acids, comparison of up to five states can be performed [59]. For a higher number
of states, pairwise comparison can be done, using one common SILAC labelled re-
ference as internal standard. Notably, labelled internal standards can be used for
quantification of any unlabelled sample, provided that their composition overlaps
sufficiently [60].
Despite advances in labelling methods, many experimental approaches would great-
ly benefit from the availability of robust label free quantification procedures. Label
free methods are convenient and economical, omitting laborious or time-consuming
labelling steps and the need for expensive isotopically labeled reagents.
Inherently, label free quantification is less accurate than label based methods, be-
cause the different samples are only compared at the final stage of the experiment
(see fig. 1.5). Researchers have tried to deduce quantitative information from
various properties of recorded mass spectra, e. g. the summed peak area of ob-
served peptides or the number of acquired MS/MS spectra (“spectral counting”)
[61]. Our laboratory exploits the relative intensities of identified peptides, together
with recent advances in normalization algorithms for label free protein quantifica-
tion; this approach has been shown to generate reliable data when combined with
sophisticated statistical analysis of replicate experiments (J. Cox et al., submitted
to Nature Methods). Conceptual differences between label based and label free





























Figure 1.6: Label based vs Label
Free Quantitative Mass Spectro-
metry. Isotopic labelling induces a
mass shift between chemically equi-
valent peptide species (A and A*).
Quantification is based on peak ra-
tios within one spectrum. Label free
quantification maps identical pep-
tides across several LC-MS runs and
compares the respective intensities.
Adapted from ref. [62]
Many scientific questions, e. g. mathematical models of biological systems, require
absolute quantification of proteins, while isotopic labelling provides only relative
values. This issue can be solved by spiking in known amounts of synthetically
produced labelled peptides or proteins [63]. This approach is generally limited to
selected proteins of interest.
A recent study has claimed to deduce absolute quantitative information from unla-
belled samples, using the intensity information from “high flyer” peptides [64], the-
reby challenging the dogma of mass spectrometry being inherently non-quantita-
tive. It is evident that the margin of error of this method is rather wide, yet promi-
sing to provide some information where other methods are not applicable or high
precision is not required.
1.2.3 Applications of Quantitative Mass Spectrometry
Quantitative mass spectrometry can monitor every property of a biological system
that can be translated to a parameter observable in the m/z–intensity–retention
time space, thereby making it a powerful tool in all fields of life science research
[43, 57]; applications range from mapping the response of entire proteomes to
certain stimuli to the identification of protein interaction networks.
Mass spectrometry is uniquely capable of detecting posttranslational modifications
(PTMs) on proteins, which generally introduce a change in mass. With phosphory-
lation being among the most prominent PTMs, phosphoproteomics is one emerging
field in recent years [65].
Analysis of protein interaction partners is another field boosted by MS based me-
thods [66–68]. Novel interactors cannot only be identified, but also be quantified




With mass spectrometry being able to identify proteins de novo, based just on ge-
nomic information, the technology is highly valuable in the unbiased discovery of
proteins in all kinds of experiments, offering alternative approaches for robustly




2.1 The HUVEC Proteome
Mass spectrometry based proteomics offers powerful tools to study the complex
processes during in vitro angiogenesis and opens up the prospect of identifying
new angiogenic regulators with significance in vivo. The morphological changes
that HUVECs undergo when plated on Matrigel are highly reminiscent of processes
happening in the body during vessel formation and offer a unique amenability for
examination.
HUVECs usually have an elliptic appearance and adopt a characteristic polygonal
“cobblestone” morphology when grown to confluency. When seeded on Matrigel,
HUVECs adhere within the first hour and stop dividing. Capillary formation begins
after 1–2 h and is complete by 24 h [20]. Similar morphological changes occur on
Matrigel depleted in growth factors (growth factor reduced, GFR).
Figure 2.1 illustrates the differences in HUVEC morphology.




8 h 24 h
Figure 2.1: HUVEC morphology on different matrices. On gelatin coated plates, HUVECs grow
in their typical “cobblestone” morphology (left panels). When seeded on Matrigel coated dishes,
HUVECs undergo significant morphological changes and form capillary-like structures with a lumen,
highly reminiscent of capillary vascular beds in vivo.
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We designed an experiment which would allow to follow proteomic changes in
endothelial cells during capillary formation and discern regulation patterns asso-
ciated with morphological changes and changes triggered by extracellular matrices
(ECMs) or growth factors. For this purpose, HUVECs were grown to confluency
in normal culture on gelatin-coated dishes. Cells were then detached with trypsin
and seeded onto dishes coated with either Matrigel or other ECMs, which did not
induce capillary formation.
The following matrices were used:
Matrigel, basement membrane matrix extracted from the EHS sarcoma.
Matrigel GFR, , prepared from EHS tumours by a modified protocol, which pre-
serves the general composition, but eliminates most of the contained growth
factors. Similarly to normal Matrigel, it triggers the formation of capillary-like
structures.
Matrigel diluted 1:1000 contains all potentially involved factors, albeit in low
concentrations. It is only able to trigger cell adhesion, but no capillary mor-
phogenesis.
Laminin, extracted from the EHS sarcoma. Laminins are major basal lamina pro-
teins and laminin 1 is the main component of Matrigel. Laminin 1 alone is
not sufficient to trigger capillary morphogenesis of HUVECs, however in com-
bination with a collagen I gel, laminin triggers elongation and anastomosing
network formation and is therefore suggested to act as the principal factor
during this process [20].
Fibronectin (FN), an ECM glycoprotein, is a general ligand for various integrins
[70] and promotes rapid adhesion of many cell types, including HUVECs.
Both fibronectin and integrins have been shown to function in embryonic
cardiovascular development and tumour angiogenesis [15, 71].
Bovine serum albumin (BSA) serves as general negative control, since adhesion
on BSA coated culture dishes relies on ECM proteins produced by the cells
themselves.
Remaining cells in suspension were harvested as the time point zero. For quantifi-
cation, lysates were mixed 2:1 with SILAC labelled internal standard (see section
A.1) prior to in gel digestion and mass spectrometric analysis.
The experimental design is outlined in fig. 2.2
Given the kinetics of the process of capillary morphogenesis, cells on Matrigel were
harvested after 12, 24 and 30 h. These time points were selected to cover the entire
reorganization of the proteome, keeping in mind that proteomic changes lag behind
their upstream stimuli.
Cells on ECMs without capillary formation, and on growth factor reduced Matrigel



























Figure 2.2: Experimental Design. HUVECs were seeded on Matrigel and the formation of capillary-
like structures was followed over the course of 30 h. In parallel, HUVECs were cultured on other EMCs
which do not trigger these morphological changes. These matrices included fibronectin, laminin,
Matrigel diluted 1:1000, and BSA. After the indicated time points, the cells were lysed and mixed
2:1 with an internal standard consisting of the lysate of SILAC labelled HUVECs in normal culture.
The mixtures were separated by 1D-SDS-PAGE, gels were cut into 18 slices and contained proteins
digested in gel. Extracted peptides were subjected to LC-MS/MS. Acquired spectra were processed
with MaxQuant for identification and relative quantification. Downstream bioinformatic analysis was
done with Perseus.
The combined HUVEC proteome dataset contained 7959 proteins, that were identi-
fied with at least one unique peptide. Requiring at least two peptides per protein re-
tained 7755 proteins. Among them were known endothelial cell markers [72] such
as CD31, Cadherin-5, ICAM1, ICAM2, Neuropilin-1, Multimerin-2, Thrombomodu-
lin, VCAM1, VEGFR1–3, and von Willebrand factor. The HUVEC proteome dataset,
providing the qualitative information about proteins expressed in this cell type, to-
gether with the quantitative information about the regulation of these proteins in
response to certain ECMs, provides a uniquely rich basis for follow-up research and
discovery of novel marker proteins for capillary morphogenesis.
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To get an estimate of the reproducibility of the biological replicates we calcula-
ted pairwise correlation coefficients between log2 transformed normalized SILAC
ratios, see table 2.1. These numbers illustrate the general reproducibility of our
experimental approach. Of note, correlation between experiments 1 and 2, which
were carried out using cells from the same pool at the same passage, just 2 days
apart, was higher than the correlations to experiment 3, which was performed with
cells at one higher passage.
Table 2.1: Correlation of SILAC ratios between biological replicates
experiment 1 vs 2 1 vs 3 2 vs 3
Suspension 0.830 0.724 0.752
12 h 0.786 0.749 0.714
24 h 0.813 0.767 0.786
30 h 0.816 0.758 0.763
GFR 0.863 0.774 0.760
Matr. dil. 0.823 0.695 0.733
Laminin 0.758 0.818 0.757
FN 0.809 0.708 0.740
BSA 0.809 0.661 0.672
average 0.812 0.739 0.742
2.1.1 Dynamics of the HUVEC Proteome
To identify proteins that are significantly regulated on distinct matrices, we perfor-
med an analysis of variance (ANOVA) using our in-house developed Perseus soft-
ware (J. Cox, unpublished). ANOVA requires independently acquired data, which
are normally distributed (this is generally the case for logarithms of SILAC ratios)
and homoscedastic (i. e. they possess the same variance within groups).
For this purpose, normalized SILAC ratios from all experiments were base-2 loga-
rithmized and grouped into 9 experimental groups representing the different ma-
trices or time points, each containing the 3 sets of data from the replicate measure-
ments.
For each identified protein group, we then performed an F-test for the null hypo-
thesis that the means of the ratios within all experimental groups are the same, and
calculated significance values for the rejection of this hypothesis. Proteins were ac-
cepted in a list of significantly regulated proteins until a false discovery rate (FDR)
of 0.01 was reached. The FDR was estimated by the method of random permuta-
tion, which compares the test statistics with statistics generated from data where
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the group assignments of measured values were randomly swapped.
These criteria resulted in a list of 1419 proteins, or roughly 18 % of the observable
HUVEC proteome, which are differentially expressed on at least one of the exami-
ned matrices or time points.
For visualization of these proteins, all logarithmized SILAC ratios were replaced by
their corresponding standard scores z = x−µ
σ
where x denotes the logarithmized
SILAC ratio, µ the mean of all measured values for this protein and σ the standard
deviation of these values. The proteins were then hierarchically clustered to receive
a dendogram of proteins with similar regulation patterns. Standard scoring allowed
to display the regulation pattern of all proteins in one representation by colour
coding (fig. 2.3).






Figure 2.3: Dynamics of the HU-
VEC proteome.
Hierarchical clustering of differen-
tially regulated HUVEC clusters pro-
teins with similar regulation pat-
terns. Each row represents one pro-
tein, the columns represent the dif-
ferent experiments, replicates are
placed adjacent to each other. Co-
lour coding is applied according to
the z-score, which denotes the re-
lative level of regulation of each
protein between the experiments;,
green indicating down- and red
upregulation. Grey colour indicated
non determined values.
Two major clusters of proteins are
recognizable and indicated with bra-
ckets labelled A and B. Further ana-
lysis was also done on subcluster C.
17
2 Results
2.1.2 Common Features of Clustered Proteins
The analysis of regulated HUVEC proteins revealed two main groups of regulation
patterns: one group of 788 proteins (labelled “cluster A” in fig. 2.3) which shows
the general tendency to be upregulated on Matrigel, and a cluster of 631 proteins
(“cluster B”), which are generally downregulated on Matrigel.
The highest peaks of regulation occurred in the 30 h Matrigel samples. The growth
factor reduced Matrigel sample behaved similarly to the regular 24 h Matrigel sam-
ple, which is in accordance to the observable phenotype. The other matrices ge-
nerally resulted in similar regulation patterns, except for some small subclusters of
the B cluster, that exhibit upregulation on e. g. diluted Matrigel.
To assess the processes associated with the observed regulation patterns, we conduc-
ted analyses based on the Gene Ontology (GO) database, the Kyoto Encyclopedia
of Genes and Genomes (KEGG) database of pathways and the Comprehensive Re-
source of Mammalian Protein Complexes (CORUM) database, whereby subclusters
were screened for enrichment of certain annotations. Cluster C was enriched for
membrane and extracellular proteins, for proteins of the respiratory chain and for
proteins involved in the metabolism of N-glycans. On the other hand, cluster B
was enriched for proteins containing pleckstrin homology (PH) domains, proteins
involved in regulation of small G-protein signalling, mTOR signalling, protein de-
phosphorylation, mitosis and regulation of the cytoskeleton.
We were particularly interested in the identification of novel marker proteins for
capillary morphogenesis. Therefore we took a closer look at cluster C, a subcluster
of A, which contains proteins that are expressed at higher levels only in HUVECs on
Matrigel over time, compared to the cells in suspension, while retaining low expres-
sion levels on matrices not triggering capillary morphogenesis. We calculated the
relative levels of upregulation and gathered the proteins with the highest increases
in table 2.2.
Among them were several histone subtypes, enzymes dealing with oxygen spe-
cies (superoxide dismutase and heme oxygenase 1), some extracellular proteins
(lactadherin and multimerin-2), molecules involved in cell adhesion (laminin γ-1,
ICAM1 and cadherins) and some known players in angiogenesis or cancer (neuropi-
lin-1, von Willebrand factor and ephrin B2). Interestingly, one previously uncha-
racterized member of the endosialin family of C-type lectins, CLEC14A, showed a
strong pattern of upregulation.
Moreover, hierarchical clustering as shown in fig. 2.3 revealed that the pattern of
CLEC14A across all experimental states closely resembled that of von Willebrand
factor, a prototypical vessel marker [73], see fig. 2.4.
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Table 2.2: Candidate Proteins for Capillary Morphogenesis of HUVECs on Matrigel
Gene Names 12 h 24 h 30 h GFR Matr. Dil. Lam. FN BSA
CDH11 4.75 9.79 11.28 9.25 6.60 5.45 9.62 7.83
CDH13 1.23 3.86 5.08 2.74 1.73 1.30 1.68 2.37
CLEC14A 3.15 6.28 8.10 4.94 1.97 1.85 2.00 2.34
ICAM1 5.83 13.78 20.94 11.65 9.99 7.89 13.15 16.54
LAMC1 10.23 13.56 29.42 15.07 3.43 6.13 1.29 1.12
MFGE8 2.87 6.18 9.43 4.31 3.06 2.72 3.49 2.44
MMRN2 1.58 3.13 3.98 2.27 1.35 1.27 1.28 1.25
NRP1 3.56 4.81 5.30 3.20 3.86 2.49 2.10 3.57
VWF 1.30 2.75 4.00 2.26 1.42 1.22 1.24 1.21
EFNB2 7.99 10.74 13.99 11.21 N.D. 4.98 2.76 5.95
CLK3 N.D. 2.18 17.31 7.56 N.D. 1.34 N.D. 0.27
COL6A3 6.95 9.41 9.34 10.32 N.D. 0.81 N.D. 0.66
FGG N.D. 4.92 24.76 8.64 N.D. N.D. 0.04 N.D.
H2AFY 7.00 9.66 7.97 14.59 2.96 N.D. 4.38 N.D.
H2BFS 2.82 7.85 6.39 6.32 0.93 1.22 0.71 0.96
HIST1H4A 4.36 9.61 8.97 12.57 1.02 1.46 0.61 1.04
HIST2H2AA3 3.69 13.38 10.66 10.02 1.21 1.52 0.63 1.24
HIST2H2AB 1.61 10.42 10.32 7.26 0.91 1.26 0.94 1.03
HIST2H3A 2.91 6.94 8.23 8.04 2.08 1.68 0.87 1.35
HIST2H3PS2 3.66 15.63 15.73 20.30 1.09 0.17 2.11 2.85
HMOX1 2.49 7.53 11.46 8.68 0.57 0.92 0.50 0.60
SOD2 1.60 4.06 5.16 4.03 2.49 2.55 2.50 2.48
Candidate proteins were selected based on their regulation pattern (see fig. 2.3, cluster C)
and on the relative level of upregulation compared to the cells in suspension. Given are the
ratios of the medians of the individual normalized SILAC ratios in one experimental group
and the cells in suspension. Proteins are indicated by the corresponding gene names.










susp 12 h 24 h 30 h GFR Dil Lam FN BSA
Figure 2.4: Closeup on Hierarchical Clustering. Figure 2.3 zoomed into the region showing
CLEC14A and von Willebrand factor (VWF). Colour coding as in fig. 2.3.
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2.2 Expression Pattern of CLEC14A
Human CLEC14A is a 490-residue, putative type I transmembrane protein, enco-
ded by a single-exon gene located on chromosome 14. By homology, CLEC14A was
categorized as fourth member of the C-type lectin family 14. Up to now, basically
nothing is known about this protein. Its significant regulation pattern in HUVECs
suggested it as a promising candidate for follow-up analysis. This pattern deter-




















































Figure 2.5: Regulation of CLEC14A under different cellular conditions.
A: Confirmation of proteomic data by western blotting. The samples were the same as for mass spec-
tromic analysis. B: HUVECs were seeded at a 1:2.4 ratio from a confluent dish, grown to confluency
(day 3) and then harvested in the course of 5 days. C: HUVECs were seeded at densities of 2 · 105–
1 · 106 cells per well of a 6-well plate and harvested 24 h later. Western blot for fig. A prepared by S.
Zanivan.
Being a homolog of endosialin and being strongly upregulated on Matrigel propo-
sed that this protein might play a role in angiogenesis. From its domain architec-
ture, we suspected it to function in cell adhesion, cell-ECM or cell-cell interaction.
Adherens junctions are the main sites of cell to cell contacts in endothelia and were
shown to be dynamically regulated by cell confluency [74]. Cadherins, some of
which we could demonstrate to be regulated similarly to CLEC14A (see table 2.2)
localize to these junctions. Moreover, the transition from subconfluent to overcon-
fluent endothelial cell culture was suggested to recapitulate aspects of the transition
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from the actively remodeling to the mature state of a vessel [74].
To probe a possible function of CLEC14A in this context, we analysed a depen-
dency of CLEC14A expression on cell confluency. For this purpose, we seeded HU-
VECs subconfluently and harvested samples in the course of several days, while the
cultures were growing from the just-confluent to the overconfluent state (fig. 2.5,
B). For comparison, HUVECs were seeded at defined cell densities and harvested af-
ter 24 h (fig. 2.5, C). CLEC14A levels are increasing over time while the cell culture
is growing overconfluent. After 6 days in culture, many cells die, thereby reducing
the effective confluency of the culture. In contrast, in cells that are directly seeded
at different densities, CLEC14A amounts increase only moderately with confluency.
These findings suggest a role of CLEC14A in the maturation blood vessels, rather
than during early events in cell adhesion.
Interestingly, besides increasing expression levels, we observed a band upshift cor-
relating with the increase in amount over time. This gave the hint to examine
posttranslational modifications of CLEC14A.
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2.3 Posttranslational Modifications of CLEC14A
CLEC14A contains one of each of the prototypical C-type lectin, sushi, EGF-like
repeat and mucin-like domains present in its paralogs. The mucin-like domain
contains many predicted O-glycosylation motifs and one site matching the N-glyco-
sylation consensus. Another possible N-glycosylation site is located in the sushi
domain. For its paralog endosialin, O-glycosylation was experimentally shown, but
no N-glycosylation could be detected [26].
The intracellular domain contains a series of serines matching kinase motifs.
Sequence features of CLEC14A, including domains and possible sites of posttrans-
lational modifications (PTMs) are depicted in fig. 2.6.
Figure 2.6: CLEC14A sequence features.
Colour coding of amino acid residues was
done according to the domains in fig. 1.3.
The predicted signal sequence and transmem-
brane region are printed in italics. All frag-
ments that were identified by mass spectrome-
try throughout this study are printed in bold-
face. Residues matching the N-glycosylation
motif NXS/T are highlighted in cyan, residues
predicted to be O-glycosylated by the NetO-
Glyc 3.1 Server [75] are indicated in purple
and cytosolic residues matching kinase motifs
according to phosida [76] are marked green.
MRPAFALCLL WQALWPGPGG GEHPTADRAG CSASGACYSL  40
HHATMKRQAA EEACILRGGA LSTVRAGAEL RAVLALLRAG  80
PGPGGGSKDL LFWVALERRR SHCTLENEPL RGFSWLSSDP 120
GGLESDTLQW VEEPQRSCTA RRCAVLQATG GVEPAGWKEM 160
RCHLRANGYL CKYQFEVLCP APRPGAASNL SYRAPFQLHS 200
AALDFSPPGT EVSALCRGQL PISVTCIADE IGARWDKLSG 240
DVLCPCPGRY LRAGKCAELP NCLDDLGGFA CECATGFELG 280
KDGRSCVTSG EGQPTLGGTG VPTRRPPATA TSPVPQRTWP 320
IRVDEKLGET PLVPEQDNSV TSIPEIPRWG SQSTMSTLQM 360
SLQAESKATI TPSGSVISKF NSTTSSATPQ AFDSSSAVVF 400
IFVSTAVVVL VILTMTVLGL VKLCFHESPS SQPRKESMGP 440
PGLESDPEPA ALGSSSAHCT NNGVKVGDCD LRDRAEGALL 480
AESPLGSSDA                                  490
2.3.1 Glycosylation of CLEC14A
Differential protein glycosylation was recently appreciated as a regulatory mecha-
nism for transmembrane receptors, particularly integrins, whose ligand affinities
were suggested to vary with their attached glycan structures [77].
To validate possible glycosylation of CLEC14A, we treated HUVEC lysates with dif-
ferent deglycosylating enyzmes and monitored the migration pattern of the protein
on an SDS gel by western blotting (fig. 2.7). Untreated CLEC14A migrates in a
broad band at an apparent molecular mass of roughly 65 kDa, compared to a theo-
retical mass of 51.6 kDa for the unmodified protein. N-deglycosylation results in a
slight downshift of the band, whereas treatment with O-glycosidase has no appa-
rent effect. However, treatment with sialidase (neuraminidase) or a combination of
sialidase and O-glycosidase caused a significant downshift of the CLEC14A band.
Take together, these results suggest that CLEC14A is both N-glycosylated and O-
glycosylated, with the O-glycoside chains being highly substituted with sialic acid.
22
2 Results
These substitutions are known to prevent cleavage by O-glycosidase alone.
O- and N-glycosylations are likely to be confined to the mucin-like domain, which
contains most of the predicted sites. Moreover, no peptide corresponding to this
domain was found throughout this study. This can be explained by low accessibility
of proteases, low ionizability of glycopeptides and unknown atomic compositions
of PTMs, all of which complicate the identification of peptides via mass spectrome-
try.
Preliminary data indicate that the upshift of the CLEC14A band with increasing
confluency (fig. 2.5, B) is not caused by differential N-glycosylation, as PNGase


























Figure 2.7: Deglycosylation of CLEC14A. HUVEC ly-
sates were treated over night with deglycosylating en-
zymes and changes in the migration pattern of CLEC14A
were analysed by SDS-PAGE and western blotting.
PNGase = peptide N-glycosidase.
2.3.2 Phosphorylation of the CLEC14A Cytoplasmic Tail
Phosphorylation is a known mechanism for regulation of the binding of PDZ domain
containing proteins to their recognition motifs, as shown for the K+-channel Kir 3.2
and the PDZ domain protein PSD-95 [31].
To further characterize CLEC14A, we investigated potential phosphorylation sites
on the CLEC14A cytoplasmic tail. We enriched the protein from HUVEC lysate
by immunoprecipitation and conducted a targeted mass spectrometric analysis of
phosphorylated peptides. For this purpose, collision-induced dissociation in combi-
nation with multistage activation [78] was performed: in the case of phosphopep-
tides, the collisional energy applied to generate MS/MS spectra generally results in
neutral loss of phosphoryl moieties, which are attached by rather weak bonds, with
the consequential lack of further fragmentation. Multistage activation induces col-
lisional activation of the product ions resulting from these neutral losses, thereby
generating more structurally informative fragment ion species and increasing the
confidence of peptide identification.
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Several possible phosphorylation sites were identified: serines 437, 483, 487 and
488. The latter three are located on the same tryptic peptide, which was found in
the singly and doubly phosphorylated form. These three residues are in the direct
vicinity of PDZ binding motif or on the motif itself, and therefore of special inter-
est concerning potential interactors. Serine 483 could be unambiguously assigned
as one location of the modification (fig. 2.8), whereas one could not definitely
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Figure 2.8: MS/MS spectrum of the CLEC14A peptide containing phospho-serine 483. Fragment
ions are labelled according to the Roepstorff-Fohlman nomenclature [79]. Fragments with neutral
losses of phosphoric acid (−97.977 Da) are marked with an asterisk.
To analyse whether the identified phosphorylation sites are regulated with the cel-
lular state, we used lysates from just-confluent and 5 days overconfluent cultures,
and from HUVECs after 20 h on Matrigel as starting material for the enrichment of
the protein by immunoprecipitation. In any case, an equivalent amount of protein
from SILAC labelled HUVECs was spiked in as internal standard.
Quantification was performed based on the SILAC ratios of the singly phosphory-
lated peptides KE(ph)SMGPPGLESDPEPAALGSSSAHCTNNGV, DRAEGALLAE(ph)
SPLGSSDA, DRAEGALLAESPLG(ph)SSDA, and DRAEGALLAESPLGS(ph)SDA. The
latter three contained one missed trypsin cleavage site. The corresponding clea-
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ved peptide could not be used since it contains no lysine or arginine and therefore
reports no SILAC ratio. Table 2.3 lists the determined protein ratio of CLEC14A
compared to the internal standard and the SILAC ratios for the individual phospho-
peptides. Data for peptides assigned to phosphoserines 487 and 488 were com-
bined, since we assumed that they correspond to the same peptide. In case of
multiple ratio counts, the averages are reported. The ratios were then normalized
by the protein ratio, to yield the relative up- or downregulation of the specific site
compared to the regulation of the protein. The protein ratio was calculated only
from unmodified and methionine-oxidized peptides.
Table 2.3: Regulation of Identified Phosphosites of CLEC14A
examined species cell state SILAC ratio L/H
measured normalized
entire protein confluent 2.13 1.00
overconfluent 3.69 1.00
on Matrigel 3.39 1.00
pSer437-peptide confluent N.D. N.D.
overconfluent 5.30 2.49
on Matrigel 10.79 5.07
pSer483-peptide confluent 3.12 1.47
overconfluent 4.88 1.32
on Matrigel 2.27 0.67
pSer487/488-peptide confluent 2.88 1.35
overconfluent 5.19 1.41
on Matrigel 5.89 1.74
Normalization was done by division by the ratio for the whole protein.
SILAC ratio L/H = ration of light vs heavy peak of a SILAC pair.
N.D. = not determined.
The numbers show that the relative phosphorylation of serines 487/488 remains
virtually unchanged with cell confluency, and is slightly increased on Matrigel. In
contrast, phosphorylation of serine 483 is reduced with confluency, and more si-
gnificantly when the cells are plated on Matrigel, thereby reducing the absolute
concentration of serine 483-phosphorylated CLEC14A. Serine 483 matches the re-
cognition motif of glycogen synthase kinase-3 (GSK3), of which isoforms α and β
have also been identified in the HUVEC proteome.
The most pronounced changes were detected for the phosphorylation of serine 437,
which is increased 2.5-fold compared to the protein in overconfluent cells and more
than 5-fold on Matrigel. Serine 437 matches the calcium/calmodulin-dependent
protein kinase type II (CAMK2) consensus motif. CAMK2 chains α, δ and γ were
found to be expressed in HUVECs.
25
2 Results
To investigate a possible evolutionary conservation of the identified phosphosites,
we aligned the amino acid sequences of the CLEC14A orthologs from different
mammals with available genome sequences (fig. 2.9). The cytoplasmic tail is gene-
rally highly conserved among mammals, with the notable exception of rodents, in
which the C-terminal sequence diverges (in case of the guinea pig) or is truncated
by about 20 residues (in case of mouse and rat). Yet, characteristics of the PDZ
binding motif are found among all sequences, with the dog and horse sequences
lacking the extreme C-terminal amino acid.
Serine 437 is only conserved among primates, whereas serines 483 and 487 are
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Figure 2.9: Alignment of the Cytoplasmic Tail of CLEC14A Orthologs. Serine residues found to




2.4 Interaction Partners of CLEC14A
The elucidation of the signalling and interaction network of CLEC14A will provide
valuable information about its cellular function.
First, we sought to identify interaction partners of the cytoplasmic tail, especially of
the PDZ binding motif, that respond to the phosphorylation state of the protein. For
this purpose, we employed the established technique of peptide pulldowns using
baits consisting of modified and unmodified synthetic peptides, corresponding to
the C-terminal 16 amino acids of CLEC14A. Since the PDZ binding motif is located
at the extreme C-terminus of the protein, it was reasonable to assume that phy-
siological interactors would, at least in part, also interact with this relatively short
peptide construct.
The mass spectrometry-based technique has its strength in identifying PTM-specific
binders against a background of abundant contaminants. It was successfully ap-
plied in our lab for the identification of proteins binding to methylated histone tails
[80] or tyrosine-phosphorylated peptides derived from insulin receptor substrates
[81]. In contrast to these studies, which relied on SILAC labelling of cells, we
followed a label free approach.
A specific PTM interactor will generally bind to the unmodified site with much less
affinity, resulting in very high ratios in SILAC-based experiments. Unlike in proteo-
mic approaches that seek to determine precise relative expression levels, numeric
values are not critical for a qualitative assessment of the interaction. The label free
approach therefore yields sufficient accuracy and supersedes the necessity for label-
ling cells.
Label free protein quantification using MaxQuant (J. Cox et al., submitted to Nature
Methods) determines ratios for individual peptides by comparing the corresponding
integrated ion currents. Normalization is delayed until all peptide signals, which
may be spread over several MS runs, have been acquired. Normalization requires a
background of unspecific binders, that are pulled down irrespective of the different
baits. Protein ratios are finally calculated by averaging peptide ratios.
Phosphorylation of serine 483 is promising to have physiological significance, since
its levels are markedly reduced in cells on Matrigel, suggesting an inhibiting role
during capillary morphogenesis, or a role during early events of this process. We
performed peptide pulldowns using the peptides biotin-SGAEGALLAESPLGSSDA
and biotin-SGAEGALLAE(ph)SPLGSSDA, coupled to streptavidin sepharose beads,
as baits.
The experiment was carried out multiple times for the purpose of statistical ana-
lysis. We noticed that similar results could be obtained with a range of similar
experimental procedures and therefore included all datasets from the optimization
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phase of the pulldown protocol into the final statistical analysis. The protocols dif-
fered slightly in the confluency of the HUVEC culture used, the number of washes,
the concentration of Igepal in the washing buffers and the amount of beads, but
generally followed the described protocol (section 4.2.1).
Dealing with protein-protein interaction, it is conceivable that some specific inter-
actors are only identified in one sample, representing their physiological interactor,
but not in the other. Given the functioning of the mass spectrometer, it will at the
same time happen that other proteins are identified in just one of the samples by
chance. To tackle this issue, all measured intensity values were log2 transformed
and missing values imputed with random numbers of a normal distribution cente-
red at the detection limit of the mass spectrometer. Then, a t-test for equal group
variance was applied and significant interactors identified by plotting the t-test p-
values against the average protein ratios (volcano plot, fig. 2.10 B).
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Figure 2.10: Peptide Pulldown of Phospho-Serine 483 Interactors.
A. Typical result of a single pulldown experiment. The normalized intensities resulting from the
phospho- and non-phospho pulldown are plotted against each other. Unspecific binders appear on
the bisecting line. Specific binders of the phosphorylated bait appear on the upper left, while binders
of the unphosphorylated peptide appear on the lower right side of this line.
B. Volcano plot of a combination of 8 peptide pulldowns. The negative logarithmic P-values of the
t-test are plotted against the average protein ratios. In this representation, significant interactors of
the phosphorylated peptide appear on the right and separated from the cloud of proteins.
We identified LanC-like protein 1 (LANCL1) as specific interactor of the peptide
carrying phosphorylated serine 483.
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To evaluate a possible role of LANCL1 in capillary morphogenesis, we reassessed
the regulation pattern of LANCL1 in our HUVEC proteome dataset. The protein was
identified throughout all experimental conditions. Its regulation pattern, shown in
table 2.4, did not pass the ANOVA test for significantly regulated proteins. However
the tendency of slight downregulation in cells on Matrigel correlates with the regu-
lation pattern of the phosphorylation of serine 483 of CLEC14A (table 2.3), thereby
substantiating the significance of the CLEC14A-phSer483–LANCL1 interaction.
Table 2.4: Regulation Pattern of LANCL1
Gene Names 12 h 24 h 30 h GFR Matr. Dil. Lam. FN BSA
LANCL1 1.04 0.79 0.74 0.88 1.06 1.26 0.92 0.87





This study provides a comprehensive dataset of proteins expressed in human um-
bilical veil endothelial cells and their regulation pattern on various extracellular
matrices. We identified almost 8000 proteins, thereby surpassing the number of
previous identifications of HUVEC proteins [82, 83]. Our dataset allows in-depth
bioinformatic, cell biological and biochemical follow-up at an extent which would
by far exceed the scope of this thesis.
We identified C-type lectin family 14 member A as a promising candidate as novel
vessel marker. CLEC14A is highly upregulated in HUVECs during the process of
capillary formation on Matrigel. Similar levels of upregulation can be observed on
a larger time scale while HUVEC cultures are growing overconfluent.
Retrospect analysis of available proteomic datasets from our lab and western blot
detection indicate that CLEC14A is missing in commonly used cell lines such as
HeLa and U2OS, and in a range of breast cancer-derived cells of non-endothelial
origin, thereby consolidating CLEC14A as an endothelial marker.
Two recent large scale studies identified CLEC14A in the context of cancer. One
recent report suggested CLEC14A (referred to as EGFR5) as a potential breast can-
cer biomarker, based on hypermethylation of CpG islands in several breast cancer
cell lines [84]. Hypermethylation generally causes silencing of a gene, which is in
accordance with our analysis of breast cancer cell lines.
The other mRNA based study found CLEC14A to be differentially expressed in ma-
lignant breast cancer samples compared to benign tumours or surrounding tissue,
with CLEC14A being among the top downregulated genes in cancer [85]. The ves-
sel marker CD31 (PECAM1) also appeared in this list of genes, suggesting that that
different degrees of vascularization of the tumours compared to benign tissues are
the reason for this finding.
Regulation of protein function by differential glycosylation was recently suggested
for ECM receptors [77]. We showed that CLEC14A is a glycoprotein and we ob-
served that PTMs might play a role during capillary formation, shown by a shift of
the CLEC14A band in western blots. Our results indicate that N-glycosylation is not
involved, while we need experimental confirmation for O-glycosylation.
Furthermore, we identified several phosphorylation sites on the short cytoplasmic
tail of CLEC14A and could demonstrate that the extent of phosphorylation is dif-




The extreme C-terminus of the protein is predicted to function as a PDZ binding
motif. We identified LANCL1 to be a specific interactor of a peptide derived from the
C-terminus of CLEC14A phosphorylated at serine 483. Further investigation will be
necessary to characterize this interaction and substantiate whether it is dependent
on the PDZ binding motif. The differences of the cytoplasmic tails of CLEC14A
orthologs in primates and rodents indicate substantial differences in downstream
signalling of CLEC14A and suggest to compare the interactomes of the human and
mouse cytoplasmic domains.
Little is known about the physiological function of LANCL1. The protein belongs
to the family of LanC-like proteins, which were suggested to catalyse modification
reactions on peptides [86]. It was initially identified in as interaction experiment
similar to our approach, using the C-terminus of the erythrocyte membrane protein
stomatin as bait [87].
In 2007, LANCL1 was appreciated for its high affinity for glutathion [88] and could
recently be cocrystallized with this molecule [89]. These findings call one study
into question which reported the interaction of LANCL1 with the Plasmodium pro-
tein PfSBP1 during malaria infection [90]; the authors used GSH-coupled beads in
combination with glutathion S-transferase (GST)-tagged PfSBP1.
Glutathion binding affinity links LANCL1 to the redox state of the cell, which is
relevant for angiogenesis, as the induction of hypoxia inducible factor 1 α (HIF1A),
which controls VEGF expression, is regulated in part by the balance of oxidized and
reduced GSH [91].
The authors of the LANCL1 crystal structure identified the SRC homology 3 domain
(SH3) of EPS8 as interaction partner of LANCL1 [89], which placed LANCL1 in
the context of cell signalling. LANCL1 mutants defective in EPS8 interaction were
shown to inhibit nerve growth factor-mediated neurite outgrowth.
So far, no PDZ domain containing proteins could be identified as interactors of the
CLEC14A C-terminus. The protein GIPC1 in particular, which was reported to in-
teract with homologous PDZ binding motifs of the endosialin family member C1qR
and integrin α-5 [27, 29], and which is expressed in HUVECs, was not found among
the interactors. Possibly the short peptide construct does not suffice to recapitulate
all physiological interactions. In the case of C1qR, GIPC1 required a juxtamem-




We are working on the establishment of the interaction network of CLEC14A. In ad-
dition to intracellular interactors, we are searching for extracellular binding part-
ners. Preliminary results from immunoprecipitation studies provide evidence for
an interaction between CLEC14A and multimerin-2 and laminin subunit α-4 (S.
Zanivan, unpublished data). Interestingly, both of these proteins are upregulated
in HUVECs on Matrigel, with multimerin-2 apprearing in the cluster of significantly
regulated proteins in direct vicinity of CLEC14A (fig. 2.4).
To gain further insight into the molecular function of CLEC14A, we plan to analyse
the phenotype of cells lacking CLEC14A expression. We could successfully knock
down the protein by RNA interference and are currently exploring differences in
cell adhesion and capillary morphogenesis by functional assays, fluorescence mi-
croscopy and the determination of the proteomic changes in CLEC14A negative
cells.
We are currently performing experiments to assess the significance of CLEC14A
in vivo. Preliminary immunohistochemical studies on tissue sections suggest that
expression of CLEC14A is confined to blood vessels and possibly glands (S. Zanivan
and P. Ostasiewicz, unpublished data) in both tumour and healthy tissue.
Similar experiments are being performed using a mouse model of pancreatic islet
carcinoma, which progresses in a series of defined states that allow to monitor the
vascularization of the tumours (“Rip-Tag mouse”, [92, 93]). Preliminary data are in
accordance with the general picture in human tissue (F. Maione, Institute for Cancer
Research & Treatment, Candiolo, Italy; unpublished data) and we plan to explore if
CLEC14A levels depend also on the stage of vessel development. We thereby hope
to substantiate our in vitro finding of CLEC14A being upregulated during capillary
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4.1 Cell Culture
4.1.1 Isolation and Culture of Human Umbilical Vein Endothelial Cells
Human umbilical vein endothelial cells (HUVECs) were cultured on polystyrene cell
culture dishes (Corning, coated with 1 % gelatin) in medium 199 GlutaMax (Gibco
Invitrogen), supplemented with 20 % fetal bovine serum (FBS, Gibco Invitrogen,
heat inactivated at 56 °C for 30 min), 100µg/ml heparin (sodium salt, Sigma-
Aldrich), 0.2 % (v/v) bovine brain extract, and 100 U/ml Penicillin, 100µg/ml
Streptomycin (Invitrogen).
HUVECs were extracted by a method derived from the Jaffe protocol [94]. Umbili-
cal cords were kindly supplied by W. Eiermann, (Rotkreuzklinikum München) and
S. Pavan (Institute for Cancer Research and Treatment, Candiolo, Italy) and stored
at 4 ◦C for up to 3 days prior to extraction. The umbilical cords were washed with
PBS, then both ends were cut, blunt needles were inserted into the vein and clam-
ped and the vessels were flushed with PBS to remove the blood. Endothelial cells
were detached from the vessel walls by incubation with 0.2 % (w/v) Collagenase A
from Clostridium histolyticum (Roche) in medium 199 for 20 min at room tempera-
ture. The cells were washed out with ∼ 40 ml of PBS, collected by centrifugation
at 1500×g for 5 min, resuspended in complete medium 199 (i. e. medium with all
supplements) and seeded on gelatin-coated 15 cm dishes.
HUVECs were subcultured by standard protocols [95] seeding the cells at ratios of
1:2 to 1:6.
4.1.2 Cell Lysis
Cells were generally lysed in modified RIPA buffer (150 mM NaCl, 50 mM Tris·HCl
pH 7.5, 10 % (v/v) glycerol, 1 mg/ml sodium deoxycholate, 1 % Igepal, protease
inhibitor (Roche)) on ice for 30 min. Cellular debris was spun down in a cooled
tabletop centrifuge at maximum speed and supernatants were collected and stored
at −20 °C. Prior to further processing, protein amounts in cell lysates were quanti-
fied by the Bradford method [96] using Biorad’s Quick-Start reagent with BSA as
standard.
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4.1.3 SILAC Labelling of HUVECs
For labelling HUVECs with stable amino acids in cell culture, 3–5 confluent primary
P0 cultures were pooled and seeded at a ratio of 1:3–1:4 onto 10 cm dishes. After
one day, the cells were switched to an analogous SILAC medium. This medium was
composed from a custom-made 10× stock of medium 199 without arginine and
lysine (Gibco Invitrogen), supplemented with 0.15 % v/w NaHCO3 to adjust the
pH, 2 mM L-glutamine and isotope labelled amino acids L-arginine-13C6
15N4 hydro-
chloride (Sigma) and L-lysine-13C6
15N2 hydrochloride (Sigma) at concentrations of
42 and 73µg/ml, respectively. The cultures were grown to confluency, while chan-
ging the medium every other day, and then subcultured as before. After 2 days at
passage 4, the cells were were switched to a medium composed with dialysed FBS
(dialysed against 150 mM NaCl using a 1 kDa cutoff dialysis tubing (Spectra/Por 7,
Spectrum Labs)) and labelled amino acids at concentrations of 56 and 97µg/ml
for Arg10 and Lys8, respectively. At the end of each passage, one dish was lysed to
check the level of incorporation of heavy amino acids.
4.1.4 Matrigel Assay
To analyse the formation of capillary-like structures, a confluent culture of HUVECs
was starved over night in M199 supplemented with only 10 % FBS and antibiotics.
The cells were then trypsinized and resuspended in starvation medium. Reference
aliquots of cells in suspension were harvested by centrifugation and lysed immedia-
tely (vide infra). The remaining cells were seeded at a density of 1 200 000 cell per
dish on 10 cm dishes coated with either Matrigel or several other matrices.
Dishes were coated with 1 ml Matrigel Basement Membrane Matrix (BD Biosciences),
diluted with 10 % M199. The matrix was applied beforehand at 4 °C and allowed
to solidify for 45 min at 37 °C.
Additional coatings included 10µg/ml fibronectin in PBS, 10µg/ml laminin in PBS,
Matrigel diluted 1:1000 in medium 199 and 3 % BSA in PBS. These coatings were
applied over night at 37 °C, except for BSA, which was applied for 1 h at 37 °C.
Cells on control matrices were all harvested after 24 h by scraping the cells in lysis
buffer. Cells on Matrigel were harvested after 12, 24 and 30 h by dissolving the
matrix with MatriSperse cell recovery solution (BD Biosciences) according to the
manufacturers recommendations. Cells were then pelleted by centrifugation and
lysed.
In case of whole proteome samples intended for quantitative mass spectrometry,
aliquots representing 100µg of protein were mixed with 50µg of SILAC-labelled
internal standard, precipitated using the methanol-chloroform method [97] and
resuspended in 1× LDS sample buffer (Invitrogen).
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4.2 Pulldown Assays
4.2.1 Peptide Pulldown
Peptide pulldowns were carried out using synthetic, N-terminally biotin coupled
peptides biotin-SGAEGALLAESPLGSSDA and biotin-SGAEGALLAE(ph)SPLGSSDA.
Synthesis was performed by the core facility of the MPI for Biochemistry, Martins-
ried, Germany on Applied Biosystems 433 A automated peptide synthesizers using
Fmoc chemistry. The peptides were lyophilized to remove organic solvent and then
resuspended in 50 mM Tris·HCl, 150 mM NaCl, adjusting the pH to 7.5.
Per pulldown sample, 50µl of streptavidin sepharose beads (30 % (v/v) slurry, GE
Healthcare) were washed twice in base buffer (150 mM NaCl, 50 mM Tris·HCl, pH
7.5, 10 % glycerol, 0.1 % Igepal), coupled with approximately 0.5 mg of peptide in
500µl base buffer for 30 min at room temperature, and washed again three times in
base buffer. Between the washing steps, the beads were pelleted by centrifugation
for 1 min at 1200×g.
Confluent HUVEC dishes were lysed in lysis buffer (base buffer, supplemented
with 100 mM Na3VO4, protease and phosphatase inhibitors without EDTA (Roche),
otherwise following the general cell lysis protocol (section 4.1.2). An equivalent of
0.5–3 mg of cellular protein was incubated with 50µl of washed, uncoupled strept-
avidin sepharose beads for 30 min at 4 ◦C on a rotating wheel. The precleared
supernatant was then added to the peptide-coupled beads and incubated likewise
for 2–3 h.
Finally, the supernatant was removed and the beads washed twice with base buffer
supplemented with PhoStop tablets, and three times with base buffer containing
only 50 mM NaCl. The beads were resuspended in 20µl of 2× LDS sample buffer
and boiled for 5 min, prior to separation by SDS-PAGE.
4.2.2 Immunoprecipitation
Immunoprecipitation of CLEC14A was carried out for enrichment of the protein for
targeted MS analysis of individual tryptic peptides. Per sample, 6µg of αCLEC14a
antibody were coupled to 40µl of Dynabead slurry (Invitrogen). The beads were
washed beforehand 2× in 100 mM sodium acetate, pH 5.0, 0.1 % Igepal, then
mixed with the antibody solution plus 1 volume of sodium acetate buffer and sha-
ken for 1 h at room temperature. After washing twice with sodium acetate buffer,
the beads were resuspended in 200 mM sodium borate, pH 9.0, 0.1 % Igepal. For
crosslinking, the beads were incubated with 25 mM dimethyl pimelimidate in so-
dium borate buffer for 45 min, and then washed again. To block remaining reactive
groups, 200 mM ethanolamine in PBS, 0.1 % Igepal, pH 8.0 were added and the
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beads shaken for 1 h. To remove residual uncoupled antibody, the beads were brie-
fly washed with 50 mM glycine, pH 2.6, 0.1 % Igepal, then immediately neutralized
with 50 mM Tris, 0,1 % Igepal, pH 7.5.
HUVECs were lysed as described, the lysate mixed with an equivalent amount of
SILAC labelled lysate and diluted to a concentration of 1 mg/ml with lysis buffer.
An equivalent of 3 mg of protein was precleared by incubation with 15µl of washed
dynabeads for 30 min at 4 ◦C. Then, the precleared lysate was directly added to the
antibody-coupled dynabeads and incubated for 1 h at 4 ◦C on a rotating wheel.
The beads were then washed twice with lysis buffer, twice with lysis buffer lacking
detergents and inhibitors, and then resuspended in 20µl of 2× LDS sample buffer
with 10 mM dithiothreitol (DTT) and boiled. The supernatant was loaded on an
SDS gel (vide infra) and the band corresponding to CLEC14A excised for further in
gel digestion and MS analysis.
Aliquots of the precleared and depleted lysates were taken for reference.
4.3 Mass Spectrometry and Data Analysis
4.3.1 1D-SDS-PAGE and In-Gel Digestion of Proteins
One-dimensional SDS polyacrylamide gel electrophoresis (1D SDS-PAGE) was used
to reduce sample complexity, followed by tryptic in-gel digestion [98]. The pro-
tein samples were separated using NuPage Novex 4–12 % Bis-Tris gels and NuPage
MOPS running buffer (Invitrogen) according to the manufacturer’s instructions.
The gels were stained with colloidal Coomassie (Initrogen). For whole proteome
samples, 18 slices were defined to yield equal protein amounts per slice according
to visual observation of the staining intensity. Gels with samples from pulldown ex-
periments were sliced to 4 slices, while eliminating highly abundant contaminant
bands. Gel slices were cut into 1 mm3 cubes, washed thoroughly 2× with 25 mM
ammonium bicarbonate (ABC), 50 % (v/v) acetonitrile (ACN) to remove the Co-
omassie staining and then dehydrated by washing with 100 % ACN. Remaining
solvent was removed in a vacuum concentrator. The dry gel pieces were rehydrated
with 10 mM DTT in 50 mM ABC and incubated for 1 h at 56 °C for reduction of disul-
fides. The resulting free thiol groups were subsequently alkylated by incubating the
samples with 55 mM iodoacetamide in 50 mM ammonium bicarbonate for 45 min
at 25 °C in the dark. The gel pieces were washed twice with 50 mM ammonium bi-
carbonate, again dehydrated with 100 % ACN, and dried in a vacuum concentrator.
Then the gel pieces were rehydrated with 12.5 ng/µl of trypsin (sequencing grade,
Promega) in 50 mM ammonium bicarbonate and incubated for 16–18 h at 37 °C for
in-gel protein digestion.
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Supernatants were transferred into fresh tubes, and the remaining peptides were
extracted by shaking the gel pieces in 30 % ACN with 3 % TFA, followed by dehy-
dration with 100 % ACN. The latter two steps were repeated. The extracts were
combined, and organic solvent was removed in a vacuum concentrator. Desalting
and concentration were carried out on RP-C18 (Empore disks, 3M) StageTips [44].
The protocol by Rappsilber et al. was upscaled ∼ 5-fold, using 2 layers of RP-C18,
adjusting to the sample amount. Samples were stored at 4 °C.
4.3.2 Nanoflow HPLC-MS/MS
Peptide mixtures were eluted from StageTips as described [44] and analysed by
online reversed-phase nanoflow liquid chromatography tandem mass spectrome-
try (LC-MS/MS) on an EASY-nLC system (Proxeon Biosystems, Odense, Denmark)
connected to the LTQ Orbitrap XL instrument (Thermo Fisher Scientific, Bremen,
Germany) equipped with a Proxeon nanoelectrospray ion source. Chromatographic
separation of the peptides took place in a 15 cm analytical column (75µm inner
diameter) in-house packed [99] with reversed-phase Reprosil Pur C18-AQ 3µm re-
sin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). Peptide mixtures were
autosampled onto the column with a flow of 500 nl/min and subsequently eluted
with a flow of 250 nl/min from 5 % to 70 % ACN in 0.5 % acetic acid, in a 140 min
gradient. The effluent from the HPLC column was directly electrosprayed into the
mass spectrometer. The instrument was operated in data-dependent mode to auto-
matically switch between full scan MS and MS/MS (MS2) acquisition. Survey full
scan MS spectra (from m/z 300–1800) were acquired in the Orbitrap with a reso-
lution of 60 000 at m/z 400 (after accumulation to a target value of 106 charges
in the linear ion trap) using the lock mass option for internal calibration of each
spectrum [48]. The five most intense ions were sequentially isolated for fragmen-
tation in the linear ion trap using collisionally induced dissociation (CID) with a
normalized collision energy of 35 % at a minimum required signal of 1000. Target
ions already selected for MS/MS were dynamically excluded for 90 s. The resulting
fragment ions were recorded in the linear ion trap with unit resolution.
In case of targeted analysis of CLEC14A derived peptides, the instrument was pro-
grammed to sequence exclusively peptides on an inclusion list, representing all
masses derived from the (optionally modified) C-terminal fragment. Additionally,
multistage activation [78] was triggered when a neutral loss was detected, which
corresponded to the mass of one phosphoryl group.
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4.3.3 Peptide Identification and Quantification
Mass spectra were processed using the MaxQuant software (version 1.0.14.3) [100,
101]. Protein and peptide identification was performed using the Mascot search en-
gine (version 2.2.2, Matrix Science [102]) by querying the concatenated forward
and reversed International Protein Index protein sequence database (IPI version
3.62) plus 175 commonly observed contaminants. The minimum required peptide
length was set to 6 amino acids, and trypsin was selected as specific enzyme[58]
(cleavage at Arg-Pro and Lys-Pro was included); two missed cleavages were allo-
wed. Carbamidomethylation (Cys) was set as fixed modification, whereas oxidation
(Met) and N-acetylation were considered as variable modifications. Mass accura-
cies were set to 7 ppm for the parent ion and 0.5 Da for fragment ions.
For the relative quantification of the peptides against their SILAC-labeled counter-
parts, our in-house developed software MaxQuant was used [100]. For protein
identification, the maximum protein and peptide false discovery rate (FDR) was set
to 0.01. Proteins were considered identified with at one peptide uniquely assigned
to the respective sequence.
4.4 Protein Biochemistry
4.4.1 Deglycosylation Assay
To assess the glycosylation state of CLEC14A, HUVEC lysates corresponding to 20µg
of protein were diluted 2-fold in 150 mM sodium phosphate, pH 7.5, 25 mM EDTA.
Then, 1 U of peptide N-glycosidase F (PNGase), 1 mU of O-glycosidase or 1 mU of
Sialidase (all enzymes from Roche) were added and incubated for 18 h at 37 ◦C.
LDS sample buffer was added and the samples were boiled prior to separation by
SDS-PAGE and western blotting.
4.4.2 Western Blotting and Immunodetection
For western blot detection, protein samples corresponding to 20µg of total lysate
were first separated by one-dimensional SDS polyacrylamide gel electrophoresis as
described (section 4.3.1) and then electrophoretically transferred [103] onto PVDF
membranes using wet blotting cells from BioRad at a constant voltage of 100 V for
1 h in transfer buffer (192 mM glycine, 20 mM Tris base, 20 % (v/v) methanol).
After blotting, the membranes were transiently stained with Ponceau S [104], de-
stained in water and dried.
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Prior to antibody detection, the membraned were rehydrated in Tris buffered saline
with 1 % Tween-20 (TBS-T). Primary antibodies (see table 4.1) were diluted in TBS-
T and incubated with the membrane for 1 h at room temperature. The membranes
were then washed 3× with TBS-T for 5 min before adding the secondary antibody
accordingly for 45 min. Finally, the membranes were washed thoroughly 3× in
TBS-T. Western detection was performed using ECL detection reagents and films
from GE Healthcare.
Table 4.1: Antibodies
Antibody Type Specificity Dilution Reference
α-CLEC14A sheep IgG human, 1:3000 R&D Systems
polyclonal extracellular domain
α-GAPDH rabbit IgG human 1:1000 Cell Signaling
polyclonal
α-vinculin mouse IgG human 1:800 Sigma
monoclonal
α-sheep donkey IgG sheep 1:5000 R&D Systems
HRP-coupled
α-rabbit donkey IgG rabbit 1:3000 GE Healthcare
HRP-coupled





A.1 SILAC Labelling of HUVECs
Lysates from SILAC labelled HUVECs were used as internal standard throughout
this study. The primary nature of HUVECs make complete labelling challenging:
They cannot be kept in culture for an unlimited number of passages without losing
their primary characteristics. Therefore, labelling had to be restricted to four pas-
sages. Moreover, cell growth was impaired when using dialysed serum. For this
reason, cells were labelled in medium with regular FBS and only switched to an
analogous medium containing FBS dialysed against a 1 kDa cutoff during the last
passage.
Generally, 2–5 confluent primary cultures were pooled to reduce variability and
switched to SILAC medium after one additional day. At the end of the fourth pas-
sage, incorporation of heavy amino acids generally reached ∼93–95 % (fig. A.1).
Figure A.1: Incorporation of Heavy Amino
Acids. Arg10, Lys8 labelled HUVEC lysate af-
ter 4 passages of labelling was analysed by
mass spectrometry. Individual ratios from
identified SILAC pairs were converted into a
relative incorporation rate 1− 1
SILAC ratio+1
and
plotted as density. Groups of peptides contai-
ning only lysine or only arginine show a simi-


















To reduce overestimation of the “light” peak due to residual unlabelled proteins
in the internal standard lysate, sample and standard were mixed at a 2:1 ratio
in case of whole proteome samples. Downstream bioinformatic analysis by the
MaxQuant software would then normalize the observed ratios to a 1:1 median,
thereby reducing this error.
Arginine to proline conversion, which occurs in some cell types and rises challenges
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